<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025983</url>
  </required_header>
  <id_info>
    <org_study_id>TH1903</org_study_id>
    <nct_id>NCT04025983</nct_id>
  </id_info>
  <brief_title>Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection</brief_title>
  <acronym>GasHp</acronym>
  <official_title>Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Gastroenterology and Hepatology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Gastroenterology and Hepatology, Vietnam</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Challenges in the treatment of Helicobacter pylori (H. pylori) include increasing&#xD;
      antimicrobial resistance and patient's low tolerance to some regimens. Lactobacillus&#xD;
      johnsonii (L. johnsonii) and Immunoglobulin Y (IgY) have been shown to decrease the amount&#xD;
      and activity of H. pylori in human stomach and can increase patient's tolerance. We conduct a&#xD;
      single-center double-masked randomized controlled trial to evaluate the effectiveness of&#xD;
      GastimunHp Plus (a product combining L. johnsonii and IgY) in improving the clearance of H.&#xD;
      pylori after six to eight weeks of treatment and side effects of H. pylori treatment. H.&#xD;
      pylori is tested by C13- or C14-urea breath test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was slow and disrupted by COVID-19.&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigational product (IP) is compared with a placebo. The IP and placebo are manufactured by the sponsor and then sent to the trial pharmacist. They are only different in a number in the package label, and only the sponsor knows which number is the IP and will call them &quot;product I&quot; and &quot;product II&quot;. This labelling is not revealed to the study team, the trial pharmacist, and the biostatistician.&#xD;
In the random number sequences generated by the biostatistician, the study numbers will be allocated to either &quot;product I&quot; or &quot;product II&quot;. The trial pharmacist is responsible for making product bags using study numbers and allocation given by the biostatistician. The product bags are transferred to the study team. In this way, the study team and patients are completely masked to the allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with negative urea breath test after 6-8 weeks</measure>
    <time_frame>Six to eight weeks after recruitment</time_frame>
    <description>Patients tested negative with Helicobacter pylori using C13- or C14-urea breath test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical improvement after 6-8 weeks</measure>
    <time_frame>Six to eight weeks after recruitment</time_frame>
    <description>Symptom resolution evaluated clinically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse effects</measure>
    <time_frame>Six to eight weeks after recruitment</time_frame>
    <description>Any adverse effects that are deemed related to the investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement of lesions on endoscopy</measure>
    <time_frame>Six to eight weeks after recruitment</time_frame>
    <description>Improvement of lesions detected on baseline on upper gastrointestinal endoscopy. Improvement was determined by expert's opinion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>GastimunHp Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sachet of GastimunHp Plus twice daily during or after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 sachet of placebo twice daily during or after meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GastimunHp Plus</intervention_name>
    <description>Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.</description>
    <arm_group_label>GastimunHp Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo contains neither IgY nor L. johnsonii.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with gastritis, duodenitis, or peptic ulcer.&#xD;
&#xD;
          -  Tested positive with Helicobacter pylori using C13- or C14-urea breath test or urease&#xD;
             test.&#xD;
&#xD;
          -  Indicated for Helicobacter pylori eradication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected malignant lesions.&#xD;
&#xD;
          -  Children under 10 years of age; pregnant or lactating women.&#xD;
&#xD;
          -  Allergic to chicken egg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Gastroenterology and Hepatology</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>peptic ulcer</keyword>
  <keyword>Lactobacillus johnsonii</keyword>
  <keyword>immunoglobin Y</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

